Merck Finds Licensing More Palatable Than Large Acquisitions
During BIO-Europe panel, AstraZeneca exec says firm’s $15.6 billion acquisition of MedImmune gives it major inroads into biologics.
During BIO-Europe panel, AstraZeneca exec says firm’s $15.6 billion acquisition of MedImmune gives it major inroads into biologics.